Form 4: NeuroOne Medical Technologies CEO David Rosa Disposes of Shares to Cover Tax Obligations
SEC Form 4 Filing
David Rosa, CEO and President of NeuroOne Medical Technologies, disposed of 2,239 shares of common stock on July 31, 2024, to cover tax obligations.
Summary
- On July 31, 2024, David A Rosa, CEO and President of NeuroOne Medical Technologies, disposed of 2,239 shares of common stock.
- The transaction was executed at a price of $0.75 per share.
- This disposal was likely to cover tax obligations related to vesting of stock or option exercise.
- Following the transaction, Mr. Rosa directly owns 1,153,422 shares of NeuroOne Medical Technologies.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The sale of shares to cover tax obligations is a common occurrence.
Stakeholder Impact
- The disposal of shares by the CEO could be perceived negatively by some shareholders, although it is a common practice for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 07/31/2024 | Date of transaction: David Rosa disposed of shares. |
| 08/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.